Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Microchip Technology Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $284.59 (market cap $39.89B), while Microchip Technology Inc. trades at $85.72 (market cap $48.11B). The key difference: Microchip Technology Inc. is the larger of the two by market cap, and Microchip Technology Inc. pays a 2.05% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MCHP | |
|---|---|---|
Market Cap | $39.89B | $48.11B |
Sector | Health | Technology |
52-Week High | $491.22 | $102.97 |
52-Week Low | $278.09 | $49.02 |
Enterprise Value | $38.15B | $53.40B |
Dividend Yield | — | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Microchip Technology (MCHP) trades at $88.59, up 0.37% with a bearish technical signal despite recent earnings beats. The stock shows elevated valuation ratios (P/E 402.68, P/S 10.25) amid weak 2025 profitability (net income margin -0.02%), though 2026 forecasts suggest recovery. Recent news highlights AI-driven semiconductor demand and new product launches in aerospace/defense. Cash flow improved to $452M in 2025, but debt remains high at $5.63B.
Outlook: Analyst consensus is strongly bullish (68% buy ratings) with a $115.45 price target, citing AI momentum and cyclical recovery. Risks include high debt, volatile earnings, and sensitivity to semiconductor cycles. The stock offers growth exposure to data center and auto markets but requires monitoring of margin improvement and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
